SCHEMBL136824

SCHEMBL136824

CCCC(CC(C)N)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 6/20 0.70
SLC1A1 P43005 5/20 0.70
SLC1A3 P43003 5/20 0.70
GRIK1 P39086 4/20 0.70
GRIK2 Q13002 4/20 0.70
CHRM1 P11229 1/20 0.62
AKR1A1 P14550 1/20 0.62
CHRM3 P20309 1/20 0.62
HTR2A P28223 1/20 0.62
HTR2C P28335 1/20 0.62
ADRA1A P35348 1/20 0.62
HRH1 P35367 1/20 0.62
DRD3 P35462 1/20 0.62
SLC6A3 Q01959 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC2 Q92769 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
CA2 P00918 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12611015 0.86 CHRM1 (0.83) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL1039720 0.83 SLC1A2 (1.00) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL5281450 0.83 SLC1A2 (1.00) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL1039722 0.83 SLC1A2 (1.00) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL20838572 0.83 SLC1A2 (1.00) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL2491997 0.82 CHRM1 (0.68) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL23565818 0.80 SLC1A2 (0.67) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL2386631 0.80 CHRM1 (0.65) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL8939043 0.80 CHRM1 (0.65) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL27749943 0.80 CHRM1 (0.65) SLC1A2SLC1A1SLC1A3GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114828841-A Use of valproic acid for reducing post-operative scarring after glaucoma surgery 参天制药株式会社 2022-07-29 CN claimed
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. (US) 2023-02-23 US disclosed
US-20230015595-A1 USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
CN-114828841-A Use of valproic acid for reducing post-operative scarring after glaucoma surgery 参天制药株式会社 2022-07-29 CN disclosed
US-20220096639-A1 THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS Frequency Therapeutics, Inc. 2022-03-31 US disclosed
EP-3921309-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. (US) 2021-12-15 EP disclosed
US-11160868-B2 Thermoreversible compositions for administration of therapeutic agents Frequency Therapeutics, Inc. (US) 2021-11-02 US disclosed
US-20210300948-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS Frequency Therapeutics, Inc. 2021-09-30 US disclosed
US-11066419-B2 1H-pyrrole-2,5-dione compounds and methods of using same Frequency Therapeutics, Inc. (US) 2021-07-20 US disclosed
US-20200316089-A1 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. 2020-10-08 US disclosed
US-20130237602-A1 VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF ALLERGAN, INC. (US) 2013-09-12 US disclosed
EP-2395970-B1 VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF ALLERGAN INC (US) 2013-04-17 EP disclosed
EP-1719768-B1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2012-04-25 EP disclosed
US-20120059060-A1 VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF ALLERGAN, INC. 2012-03-08 US disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
WO-2010093564-A1 VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF ALLERGAN, INC. (US) 2010-08-19 WO disclosed
US-20100204325-A1 VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF ALLERGAN, INC. (US) 2010-08-12 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
EP-1719768-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS Asahi Kasei Pharma Corporation (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160868-B2 Thermoreversible compositions for administration of therapeutic agents MKI67, MCL1, HSPE1 SLC1A2 3659/4885SLC1A1 3448/4885SLC1A3 3753/4885
US-20210300948-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS MCL1, PROX1, MKI67 SLC1A2 3297/4885SLC1A1 3158/4885SLC1A3 3681/4885
US-20220096639-A1 THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS MKI67, MCL1, HSPE1 SLC1A2 3659/4885SLC1A1 3448/4885SLC1A3 3753/4885
US-20200316089-A1 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME DCX, MCL1, MKI67 SLC1A2 3766/4885SLC1A1 3372/4885SLC1A3 3580/4885
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME DCX, NES, MCL1 SLC1A2 2760/4885SLC1A1 2180/4885SLC1A3 3360/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 SLC1A2 562/4885SLC1A1 432/4885SLC1A3 599/4885
US-11066419-B2 1H-pyrrole-2,5-dione compounds and methods of using same MKI67, PROX1, DCX SLC1A2 3531/4885SLC1A1 3543/4885SLC1A3 4018/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 SLC1A2 390/4885SLC1A1 246/4885SLC1A3 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.